Hospital readmission risk in pediatric patients was higher in those who were first admitted for RSV than in those who were first admitted for influenza or hMPV.

MONDAY, July 7, 2025 (HealthDay News) — Adults as young as 50 may now qualify for an RSV vaccine if they have certain health ...

In the U.S., respiratory syncytial virus (RSV) is responsible for up to 160,000 hospitalizations and 10,000 deaths annually among adults aged 65 and older.

The recommendation for Enflonsia is indicated for respiratory syncytial virus prevention in infants under eight months of age ...

The Food and Drug Administration has approved three vaccines for RSV — GSK's GSK.L Arexvy, Moderna's MRNA.O mRESVIA and ...

Frailty was a significant predictor of severe outcomes and hospitalization characteristics in older adults hospitalized with RSV infection.

Expanded Approval: Moderna’s mRESVIA vaccine is now FDA-approved for adults aged 18–59 years with an increased risk for respiratory syncytial virus (RSV)-related lower respiratory tract disease.

The Trump administration appears to be expanding RSV vaccinations to some adults starting at age 50 instead of 60 ...

Regulator warns of small risk of serious condition in people having RSV jab - Guillain-Barre syndrome is a rare but serious condition which needs urgent treatment in hospital to prevent it progressing ...

Respiratory syncytial virus is common but it can be dangerous for some infants and young kids. Here's everything parents need ...

The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 ...

RAHWAY, N.J., June 09, 2025--U.S. FDA Approves Merck’s ENFLONSIA for Prevention of RSV Lower Respiratory Tract Disease in Infants Born During or Entering Their First RSV Season ...